BEVERLY HILLS, Calif.,
May 14
/PRNewswire-FirstCall/ -- OXIS INTERNATIONAL, INC. (OTC Bulletin Board: OXIS, Paris: OXI), announced today that its senior management will be presenting on Tuesday, May 18th at 2:50pm BST at the Rodman & Renshaw Annual Global Investment Conference. Chairman & CEO Tony Cataldo and President Bernie Landes will be unveiling the commercialization and rollout plan of OXIS' powerful patent and IP portfolio. The company's plan, focused on gaining a significant stronghold in the multibillion dollar Nutraceuticals, Functional Food, Cosmeceuticals, and Animal Health markets, is expected to garner strong attention among the over 1,000 investors attending the conference. Shareholders are welcome to follow the presentation using this link: http://www.wsw.com/webcast/rrshq17/oxis.ob
"We are indeed pleased to present OXIS International at such a prestigious event. We look forward to using this platform to make the investment community acutely aware of the disruptive IP that OXIS will be bringing to market through its new business strategy. Leveraging these unique assets will allow OXIS to see the potential its 30 plus years of scientific work has earned." Tony Cataldo, CEO.
Contact the Company at: 310-860-5184 for additional information about OXIS, or visit our web site: www.oxis.com .
About OXIS International, Inc.
OXIS International, Inc. develops technologies and products to research, diagnose, treat and prevent diseases of oxidative stress/inflammation associated with damage from free radical and reactive oxygen species (ROS). The company holds the rights to several therapeutic classes of compounds in the area of oxidative stress, and has focused commercialization programs that include SOD (superoxide dismutase), MPO (myeloperoxidase), GPx (glutathione peroxidase), as well as a highly potent antioxidant, Ergothioneine, that may be sold over-the-counter (OTC) as a dietary supplement.
Forward-Looking Statement
This press release contains forward-looking statements that involve numerous risks and uncertainties. Actual results, performance or achievements could differ materially from those anticipated in such forward-looking statements as a result of certain factors, including those set forth in the Company's filings with the Securities and Exchange Commission.
SOURCE OXIS International, Inc.
Advertisement
"We are indeed pleased to present OXIS International at such a prestigious event. We look forward to using this platform to make the investment community acutely aware of the disruptive IP that OXIS will be bringing to market through its new business strategy. Leveraging these unique assets will allow OXIS to see the potential its 30 plus years of scientific work has earned." Tony Cataldo, CEO.
Advertisement
Contact the Company at: 310-860-5184 for additional information about OXIS, or visit our web site: www.oxis.com .
About OXIS International, Inc.
OXIS International, Inc. develops technologies and products to research, diagnose, treat and prevent diseases of oxidative stress/inflammation associated with damage from free radical and reactive oxygen species (ROS). The company holds the rights to several therapeutic classes of compounds in the area of oxidative stress, and has focused commercialization programs that include SOD (superoxide dismutase), MPO (myeloperoxidase), GPx (glutathione peroxidase), as well as a highly potent antioxidant, Ergothioneine, that may be sold over-the-counter (OTC) as a dietary supplement.
Forward-Looking Statement
This press release contains forward-looking statements that involve numerous risks and uncertainties. Actual results, performance or achievements could differ materially from those anticipated in such forward-looking statements as a result of certain factors, including those set forth in the Company's filings with the Securities and Exchange Commission.
SOURCE OXIS International, Inc.
